PEP-T1.
Nuts and Bolts of Lutetium 177 (Lu-177) Therapies KE Berry*, Fox Chase Cancer Center
Abstract: Commercially available in the US today are Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer. Worldwide there are 98 clinical trials recruiting patients as of February 20, 2023, 35 of which are open in the US. There are studies of new Lu-177 drugs to treat small cell lung cancer, midgut carcinoid tumors, prostate cancer, neuroendocrine tumors that are labeled as “completed” in clinicaltrials.gov. We can clearly anticipate that there are more Lutetium 177 commercial offerings in the pipeline. So where so you start?
Start with this PEP course. This course will cover everything from the basics of what is Lutetium 177, the basic theory of Lu-177 as a cancer agent, licensing considerations, staffing requirements, differences between commercially available therapies, administration options, extravasations, contamination prevention, discharge instructions, how to handle the death of a patient, and lots of lessons learned along the way. The goal of this course is to prepare you to confidently speak with your team when one of your physicians says “I want to use Lutathera” or “I want to use Pluvicto on my patient.”
|
